Latest Conference Articles

November 19th 2017, 3:08am

EMUC Congress

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

November 18th 2017, 10:56pm

EMUC Congress

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

November 18th 2017, 8:05pm

EMUC Congress

Kerstin Junker, MD, associate professor, Department of Urology, Universit

November 18th 2017, 7:37pm

EMUC Congress

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

November 18th 2017, 4:29am

EMUC Congress

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

November 18th 2017, 3:44am

EMUC Congress

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

November 18th 2017, 3:13am

EMUC Congress

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

November 18th 2017, 2:23am

EMUC Congress

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

November 18th 2017, 1:41am

EMUC Congress

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

November 17th 2017, 9:40pm

EMUC Congress

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

November 17th 2017, 9:34pm

EMUC Congress

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

November 16th 2017, 1:34am

PER® Chemotherapy Foundation Symposium (CFS)

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

November 15th 2017, 10:13pm

PER® Chemotherapy Foundation Symposium (CFS)

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

November 11th 2017, 2:47am

PER® Chemotherapy Foundation Symposium (CFS)

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

November 11th 2017, 2:46am

PER® Chemotherapy Foundation Symposium (CFS)

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

November 11th 2017, 2:15am

PER® Chemotherapy Foundation Symposium (CFS)

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

November 11th 2017, 12:14am

PER® Chemotherapy Foundation Symposium (CFS)

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

November 10th 2017, 11:15pm

PER® Chemotherapy Foundation Symposium (CFS)

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

November 10th 2017, 2:47am

SITC Meeting

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

November 10th 2017, 1:44am

PER® Chemotherapy Foundation Symposium (CFS)

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.